Tumor marker levels were additionally measured in all patients based on the malignancy type: carcinoembryonic antigen (CEA) and CA19-9 for colorectal cancer (CRC), gastric cancer (GC), and pseudomyxoma peritonei (PMP); and CA125 for ovarian cancer (OC). This evidence concerns the gene CEACAM5 and colorectal cancer.